Table 5.

Survival analyses in subgroup 1

	Subgroup 1A (n = 239)a				Subgroup 1B (n = 63)b
	PFS		OS		PFS		OS
	Multivariate analyses	Univariate analyses (p)	Multivariate analyses	Univariate analyses (p)	Multivariate analyses	Univariate analyses (p)	Multivariate analyses	Univariate analyses (p)
Median, mon	2.8 (2.3–3.4)		5.7 (5.0–6.4)		4.1 (2.8–5.4)		11.4 (8.9–13.9)
NLR ≥ 3.8	1.75 (1.263–2.423)	0.001	9.412 (4.386–20.201)	0.001	2.894 (1.352–6.193)	0.006	1.414 (1.062–1.884)	0.018
PLR ≥ 180	1.277 (0.963–1.693)	0.089	2.631 (1.445–4.79)	0.002	1.240 (0.934–1.646)	0.137	2.544 (1.299–4.983)	0.006
CRP-albumin ratio ≥ 3.85	1.347 (1.016–1.787)	0.039	2.411 (1.333–4.363)	0.004	2.126 (1.105–4.092)	0.024	1.586 (1.202–2.092)	0.001

Values are presented as hazard ratio (95% confidence interval).

PFS, progression free survival; OS, overall survival; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein.

^aSubgroup 1A: The group of patients who had not received any invasive procedures within 30 days prior to the start of chemotherapy.

^bSubgroup 1B: The group of patients who had received any invasive procedures within 30 days.